Wall Street Zen lowered shares of Novanta (NASDAQ:NOVT – Free Report) from a buy rating to a hold rating in a research report released on Sunday,Wall Street Zen reports.
Other research analysts have also recently issued research reports about the company. Robert W. Baird decreased their price target on Novanta from $194.00 to $175.00 and set an “outperform” rating for the company in a research note on Thursday. Zacks Research cut Novanta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Finally, Weiss Ratings downgraded Novanta from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, November 10th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novanta presently has an average rating of “Hold” and a consensus target price of $175.00.
Get Our Latest Stock Report on Novanta
Novanta Stock Performance
NASDAQ NOVT opened at $118.88 on Friday. The stock’s fifty day moving average price is $140.29 and its 200-day moving average price is $142.25. The company has a current ratio of 1.18, a quick ratio of 0.76 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.50 billion, a P/E ratio of 90.75, a P/E/G ratio of 2.58 and a beta of 1.71. Novanta has a 12 month low of $98.27 and a 12 month high of $176.38.
Novanta (NASDAQ:NOVT – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The technology company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.97 by $0.08. The company had revenue of $305.01 million for the quarter, compared to the consensus estimate of $301.02 million. Novanta had a net margin of 4.89% and a return on equity of 10.23%. Novanta’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.87 EPS. As a group, equities analysts forecast that Novanta will post 3.68 EPS for the current fiscal year.
Institutional Investors Weigh In On Novanta
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Aberdeen Group plc purchased a new position in Novanta in the 3rd quarter worth approximately $552,152,000. Bamco Inc. NY purchased a new stake in shares of Novanta in the second quarter valued at $137,984,000. William Blair Investment Management LLC purchased a new stake in Novanta in the 2nd quarter worth about $124,254,000. Barrow Hanley Mewhinney & Strauss LLC bought a new stake in shares of Novanta during the 2nd quarter worth approximately $71,407,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Novanta during the second quarter valued at $55,926,000. Hedge funds and other institutional investors own 98.35% of the company’s stock.
Novanta Company Profile
Novanta develops and manufactures precision technologies used in medical and advanced industrial applications. Its products include photonics and laser components, precision motion-control systems, machine-vision technologies, and related equipment and software. The company’s technologies are used in areas such as medical and surgical systems, life sciences, robotics, and industrial automation. Novanta serves customers internationally, with operations and customers across North America, Europe, and Asia.
Featured Articles
- Five stocks we like better than Novanta
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
